Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.00 -10.3%	$1.57	$0.87 ▼ $6.37	$202.42M	0.86	813,734 shs	1.72 million shs
IMNM Immunome	$9.91 +2.6%	$9.56	$5.15 ▼ $16.73	$862.57M	1.93	1.02 million shs	524,669 shs
MLYS Mineralys Therapeutics	$13.51 +2.4%	$14.20	$8.24 ▼ $18.38	$880.58M	-0.29	869,403 shs	875,093 shs
ZYME Zymeworks	$13.02 +4.7%	$12.93	$9.03 ▼ $17.70	$907.27M	1.26	535,609 shs	366,843 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+3.72%	+43.87%	+38.51%	+100.90%	-56.10%
IMNM Immunome	-0.31%	-11.78%	+11.81%	+22.12%	-25.23%
MLYS Mineralys Therapeutics	+1.46%	+1.23%	-8.97%	-13.17%	+19.69%
ZYME Zymeworks	+3.49%	-1.27%	-6.75%	+7.15%	+22.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
ALEC Alector	4.0929 of 5 stars	3.1	3.0	4.5	3.0	2.5
IMNM Immunome	1.7578 of 5 stars	3.5	0.0	0.0	2.5	2.5
MLYS Mineralys Therapeutics	2.3876 of 5 stars	3.4	1.0	0.0	2.5	4.2
ZYME Zymeworks	3.2525 of 5 stars	3.5	4.0	0.0	3.1	3.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.29	Hold	$4.17	108.33% Upside
IMNM Immunome	3.00	Buy	$23.14	133.53% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	138.71% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.43	64.58% Upside

Current Analyst Ratings Breakdown

Latest ALEC, MLYS, IMNM, and ZYME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $22.00
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	2.01	N/A	N/A	$1.29 per share	1.55
IMNM Immunome	$9.04M	95.42	N/A	N/A	$2.27 per share	4.37
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
ZYME Zymeworks	$122.87M	7.38	N/A	N/A	$6.63 per share	1.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	N/A
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	N/A
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	10/30/2025 (Estimated)

Latest ALEC, MLYS, IMNM, and ZYME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	-$0.66	+$0.12	-$0.66	N/A	N/A
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.13	3.78	3.78
IMNM Immunome	N/A	12.13	12.13
MLYS Mineralys Therapeutics	N/A	26.48	26.48
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
IMNM Immunome	44.58%
MLYS Mineralys Therapeutics	84.46%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.70%
IMNM Immunome	7.69%
MLYS Mineralys Therapeutics	33.24%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
IMNM Immunome	40	87.04 million	80.35 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	43.51 million	Optionable
ZYME Zymeworks	460	69.68 million	67.56 million	Optionable

ALEC, MLYS, IMNM, and ZYME Headlines

Recent News About These Companies

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 12 at 10:55 AM | zacks.com

Citigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12 at 9:47 AM | marketbeat.com

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12 at 4:04 AM | americanbankingnews.com

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

August 12 at 3:38 AM | marketbeat.com

Zymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11 at 8:16 PM | finanznachrichten.de

Zymeworks Strengthens Leadership with New Board Appointments

August 11 at 6:40 AM | tipranks.com

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors

August 11 at 6:19 AM | quiverquant.comQ

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11 at 6:19 AM | financialpost.comF

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 11 at 2:15 AM | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10 at 2:16 PM | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Given Consensus Rating of "Moderate Buy" by Analysts

August 10 at 2:17 AM | americanbankingnews.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9 at 7:23 AM | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8, 2025 | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...

July 30, 2025 | finance.yahoo.com

FDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors

July 30, 2025 | targetedonc.comT

Zymeworks Inc.: Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 28, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, MLYS, IMNM, and ZYME Company Descriptions

Alector NASDAQ:ALEC

$2.00 -0.23 (-10.31%)

Closing price 04:00 PM Eastern

Extended Trading

$2.09 +0.09 (+4.50%)

As of 05:34 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$9.91 +0.25 (+2.59%)

Closing price 04:00 PM Eastern

Extended Trading

$9.90 -0.01 (-0.05%)

As of 05:04 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Mineralys Therapeutics NASDAQ:MLYS

$13.51 +0.32 (+2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$14.14 +0.63 (+4.67%)

As of 05:30 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Zymeworks NYSE:ZYME

$13.02 +0.58 (+4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$12.94 -0.07 (-0.58%)

As of 04:46 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time